1. Home
  2. SDOT vs AZTR Comparison

SDOT vs AZTR Comparison

Compare SDOT & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sadot Group Inc.

SDOT

Sadot Group Inc.

HOLD

Current Price

$0.28

Market Cap

3.2M

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.23

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDOT
AZTR
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.5M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
SDOT
AZTR
Price
$0.28
$0.23
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
14.5M
465.0K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
490.91
5.06
EPS
N/A
N/A
Revenue
$7,929,137.00
N/A
Revenue This Year
$12.76
N/A
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
60.08
N/A
52 Week Low
$0.24
$0.10
52 Week High
$13.02
$1.40

Technical Indicators

Market Signals
Indicator
SDOT
AZTR
Relative Strength Index (RSI) 22.36 50.81
Support Level $0.24 $0.21
Resistance Level $0.96 $0.26
Average True Range (ATR) 0.16 0.02
MACD -0.09 -0.00
Stochastic Oscillator 2.53 42.09

Price Performance

Historical Comparison
SDOT
AZTR

About SDOT Sadot Group Inc.

Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: